Evidence map›Paper›PMID 38530082›Full record

ArticleNucleic acid therapeutics2024

Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Adi Idris, Surya Shrivastava, Aroon Supramaniam, Roslyn M Ray, Galina Shevchenko, Dhruba Acharya, Nigel A J McMillan, Kevin V Morris

Open access · hybridAbstract read
In one paragraph

Article in Nucleic acid therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Adi IdrisSchool of Pharmacy and Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, Brisbane, Australia.ORCID 0000-0002-0562-1549
Surya ShrivastavaCenter for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, Duarte, California, USA.
Aroon SupramaniamSchool of Pharmacy and Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, Brisbane, Australia.
Roslyn M RayCenter for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, Duarte, California, USA.
Galina ShevchenkoCenter for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, Duarte, California, USA.
Dhruba AcharyaSchool of Pharmacy and Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, Brisbane, Australia.
Nigel A J McMillanSchool of Pharmacy and Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, Brisbane, Australia.ORCID 0000-0002-9471-1406
Kevin V MorrisCentre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Brisbane, Australia.
Griffith University · AUCity of Hope · USQueensland University of Technology · AU

Funding

Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brainR01MH134389 · NIMH · GEORGE MASON UNIVERSITY · PI Fatah Kashanchi · 2023 to 2026
$2.0M
NIMH NIH HHS 1R01MH134389-01
6 · The paper itself

Abstract

Long antisense RNAs (asRNAs) have been observed to repress HIV and other virus expression in a manner that is refractory to viral evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) disease, has a distinct ability to evolve resistance around antibody targeting, as was evident from the emergence of various SARS-CoV-2 spike antibody variants. Importantly, the effectiveness of current antivirals is waning due to the rapid emergence of new variants of concern, more recently the omicron variant. One means of avoiding the emergence of viral resistance is by using long asRNA to target SARS-CoV-2. Similar work has proven successful with HIV targeting by long asRNA. In this study, we describe a long asRNA targeting SARS-CoV-2 RNA-dependent RNA polymerase gene and the ability to deliver this RNA in extracellular vesicles (EVs) to repress virus expression. The observations presented in this study suggest that EV-delivered asRNAs are one means to targeting SARS-CoV-2 infection, which is both effective and broadly applicable as a means to control viral expression in the absence of mutation. This is the first demonstration of the use of engineered EVs to deliver long asRNA payloads for antiviral therapy.

Indexed as

COVID-19Extracellular VesiclesRNA, AntisenseSARS-CoV-2AnimalsAntiviral AgentsChlorocebus aethiopsCOVID-19 Drug TreatmentHumansRNA-Dependent RNA PolymeraseVero CellsAntiviral AgentsRNA, AntisenseRNA-Dependent RNA Polymeraseantisense RNAexosomeextracellular vesiclesneural stem cellSARS-COV-2

Identifiers

PMID38530082
PMCPMC11296208
OpenAlexW4393200667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.